Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV

被引：32

作者：

Bollinger, Robert C. ^{[1
]}

Thio, Chloe L. ^{[1
]}

Sulkowski, Mark S. ^{[1
]}

McKenzie-White, Jane ^{[1
]}

Thomas, David L. ^{[1
]}

Flexner, Charles ^{[1
]}

机构：

[1] Johns Hopkins Univ, Sch Med, Baltimore, MD 21287 USA

来源：

LANCET HIV | 2020年 / 7卷 / 06期

关键词：

ANTIRETROVIRAL THERAPY; PREEXPOSURE PROPHYLAXIS; INFECTION; ADULTS; HBV; INDIVIDUALS; COINFECTION; PREVALENCE; TENOFOVIR; MEN;

D O I：

10.1016/S2352-3018(19)30342-X

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The first long-acting formulations of HIV drugs are undergoing regulatory review for use in maintenance of viral suppression in people with HIV. Although these novel drug formulations could contribute greatly to HIV treatment and prevention efforts, their lack of activity against hepatitis B virus (HBV) could limit their global impact, particularly in populations with high burdens of both HIV and HBV. An urgent need for greater investment in research and development of long-acting drugs with dual activity against HIV and HBV exists. Access to long-acting HIV drug formulations with dual activity against HBV would be transformative and have a great impact on efforts to prevent, treat, and eradicate both of these important global epidemics.

引用

页码：E443 / E448

页数：6

共 70 条

[1]

[Anonymous], CONTRIB E CON2022

[2]

[Anonymous], REACH

[3]

[Anonymous], 2019, TOP ANTIVIR MED

[4]

[Anonymous], N ENGL J MED

[5]

[Anonymous], 2014, Guidelines on post-exposure prophylaxis for HIV and the use of co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents and children

[6]

Azar A., 2019, ENDING HIV EPIDEMIC

[7] Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women [J].

Baeten, J. M. ;

Donnell, D. ;

Ndase, P. ;

Mugo, N. R. ;

Campbell, J. D. ;

Wangisi, J. ;

Tappero, J. W. ;

Bukusi, E. A. ;

Cohen, C. R. ;

Katabira, E. ;

Ronald, A. ;

Tumwesigye, E. ;

Were, E. ;

Fife, K. H. ;

Kiarie, J. ;

Farquhar, C. ;

John-Stewart, G. ;

Kakia, A. ;

Odoyo, J. ;

Mucunguzi, A. ;

Nakku-Joloba, E. ;

Twesigye, R. ;

Ngure, K. ;

Apaka, C. ;

Tamooh, H. ;

Gabona, F. ;

Mujugira, A. ;

Panteleeff, D. ;

Thomas, K. K. ;

Kidoguchi, L. ;

Krows, M. ;

Revall, J. ;

Morrison, S. ;

Haugen, H. ;

Emmanuel-Ogier, M. ;

Ondrejcek, L. ;

Coombs, R. W. ;

Frenkel, L. ;

Hendrix, C. ;

Bumpus, N. N. ;

Bangsberg, D. ;

Haberer, J. E. ;

Stevens, W. S. ;

Lingappa, J. R. ;

Celum, C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (05) :399-410

[8] Treatment and prevention of HIV infection with long-acting antiretrovirals [J].

Benitez-Gutierrez, Laura ;

Soriano, Vicente ;

Requena, Silvia ;

Arias, Ana ;

Barreiro, Pablo ;

de Mendoza, Carmen .

EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (05) :507-517

[9] Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine [J].

Bessesen, M ;

Ives, D ;

Condreay, L ;

Lawrence, S ;

Sherman, KE .

CLINICAL INFECTIOUS DISEASES, 1999, 28 (05) :1032-1035

[10]

Bhattacharya DGR, 2019, C RETR OPP INF SEATT

← 1 2 3 4 5 6 7 →